2024-514181-39-00RecruitingPhase 3
ISEE-RCC study
Intrapatient comparison of 68Ga-gozetotide (PSMA) PET and 89Zr-girentuximab PET in clear cell renal cell carcinoma (ISEE-RCC)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 May 2026
Brief summary (registry, in English)
This explorative study aims to investigate and compare (both visually and semi-quantitatively) the tumor detection rates of 68Ga-gozetotide (PSMA) PET and 89Zr-DFO-girentuximab PET in patients suspected of having primary, recurrent or metastatic ccRCC.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 23 Oct 2024
- Start date
- 23 Sept 2025
- Lead sponsor
- Stichting Radboud universitair medisch centrum
- Diseases
- Kidney cancer
- EU CT number
- 2024-514181-39-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Administration of tyrosine kinase inhibitors within 1 month prior to inclusion.
- Administration of a radioisotope within 10 physical half-lives prior to study enrollment.
- Possibility of pregnancy (anamnestic, if ambiguity; a pregnancy test will be conducted prior to the PET/CT) or lactation.
Other illness
- History of a CAIX-negative, PSMA negative or non-clear cell RCC.
- Second active malignancy (except basal-cell carcinoma).
- Known hypersensitivity or formation of human anti-chimeric antibodies (HACA) against girentuximab or DFO.
Lab values
- Renal insufficiency with GFR ≤ 45 mL/min/1.73m2
Other
- No verbal and written command of Dutch language
Who the study is looking for
- ≥ 18 years
- Suspicion of metastatic ccRCC on conventional contrast-enhanced CT (performed max. 4 weeks prior to the PET scan). Diagnosis may or may not be proven by biopsy prior to inclusion in the study. Primary tumor may or may not be in place.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.